Depressive-Like Effects of the κ-Opioid Receptor Agonist Salvinorin A on Behavior and Neurochemistry in Rats

Endogenous opioids seem to play a critical role in the regulation of mood states. For example, there is accumulating evidence that stimulation of κ-opioid receptors, upon which the endogenous opioid dynorphin acts, can produce depressive-like behaviors in laboratory animals. Here we examined whether systemic administration of salvinorin A (SalvA), a potent and highly selective κ-opioid agonist, would produce depressive-like effects in the forced swim test (FST) and intracranial self-stimulation (ICSS) test, which are behavioral models often used to study depression in rats. We extracted, isolated, and purified SalvA from Salvia divinorum plant leaves and examined its effects on behavior in the FST and ICSS test across a range of doses (0.125–2.0 mg/kg) after systemic (intraperitoneal) administration. SalvA dose dependently increased immobility in the FST, an effect opposite to that of standard antidepressant drugs. Doses of SalvA that produced these effects in the FST did not affect locomotor activity in an open field. Furthermore, SalvA dose dependently elevated ICSS thresholds, an effect similar to that produced by treatments that cause depressive symptoms in humans. At a dose that caused the depressive-like effects in both the FST and ICSS assays, SalvA decreased extracellular concentrations of dopamine (DA) within the nucleus accumbens (NAc), a critical component of brain reward circuitry, without affecting extracellular concentrations of serotonin (5-HT). These data provide additional support for the hypothesis that stimulation of brain κ-opioid receptors triggers depressive-like signs in rats and raise the possibility that decreases in extracellular concentrations of DA within the NAc contribute to these effects.

[1]  C. Gleiter,et al.  Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage). , 2005, Pharmacopsychiatry.

[2]  M. Todtenkopf,et al.  Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats , 2004, Psychopharmacology.

[3]  Donzanti Ba,et al.  Kappa agonist-induced reduction in dopamine release: site of action and tolerance. , 1992 .

[4]  R. Spanagel,et al.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Eric J. Nestler,et al.  Inhibition of cAMP Response Element-Binding Protein or Dynorphin in the Nucleus Accumbens Produces an Antidepressant-Like Effect , 2002, The Journal of Neuroscience.

[6]  V. Pickel,et al.  Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell. , 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[7]  R. Wise.  Drug-activation of brain reward pathways. , 1998, Drug and alcohol dependence.

[8]  E. Nestler,et al.  Altered Responsiveness to Cocaine and Increased Immobility in the Forced Swim Test Associated with Elevated cAMP Response Element-Binding Protein Expression in Nucleus Accumbens , 2001, The Journal of Neuroscience.

[9]  Michael Rickels,et al.  Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants , 1995, Psychopharmacology.

[10]  V. Pickel,et al.  Cellular Sites for Dynorphin Activation of κ-Opioid Receptors in the Rat Nucleus Accumbens Shell , 1999, The Journal of Neuroscience.

[11]  B. Cohen,et al.  Dynorphinergic gaba neurons are a target of both typical and atypical antipsychotic drugs in the nucleus accumbens shell, central amygdaloid nucleus and thalamic central medial nucleus , 2003, Neuroscience.

[12]  B. H. Hill,et al.  An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. , 2000, Journal of substance abuse treatment.

[13]  R. Porsolt,et al.  Depression: a new animal model sensitive to antidepressant treatments , 1977, Nature.

[14]  E. Butelman,et al.  Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors , 2005, Psychopharmacology.

[15]  G. Di Chiara,et al.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Rompré,et al.  The curve-shift paradigm in self-stimulation , 1986, Physiology & Behavior.

[17]  L. Swanson.  The Rat Brain in Stereotaxic Coordinates, George Paxinos, Charles Watson (Eds.). Academic Press, San Diego, CA (1982), vii + 153, $35.00, ISBN: 0 125 47620 5 , 1984 .

[18]  T. Shippenberg,et al.  Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists. , 1987, Brain research.

[19]  R. Wise.  Neuroleptics and operant behavior: The anhedonia hypothesis , 1982, Behavioral and Brain Sciences.

[20]  B. Cohen,et al.  New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors. , 2005, Bioorganic & medicinal chemistry.

[21]  T. Kemper,et al.  Dorsal raphe, substantia nigra and locus coeruleus: Interconnections with each other and the neostriatum , 1977, Brain Research Bulletin.

[22]  Bryan L Roth,et al.  Salvinorin A, an Active Component of the Hallucinogenic Sage Salvia divinorum Is a Highly Efficacious κ-Opioid Receptor Agonist: Structural and Functional Considerations , 2004, Journal of Pharmacology and Experimental Therapeutics.

[23]  S. D. Glick,et al.  U50,488, a κ opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats , 1994, Neuroscience Letters.

[24]  Athina Markou,et al.  Assessing antidepressant activity in rodents: recent developments and future needs. , 2002, Trends in pharmacological sciences.

[25]  E. Nestler,et al.  The Mesolimbic Dopamine Reward Circuit in Depression , 2006, Biological Psychiatry.

[26]  T. Shippenberg,et al.  Sensitization to the Behavioral Effects of Cocaine: Modulation by Dynorphin and κ-Opioid Receptor Agonists , 1997, Pharmacology Biochemistry and Behavior.

[27]  H. Emrich,et al.  Psychotomimesis mediated by kappa opiate receptors , 1986, Science.

[28]  G. Bigelow,et al.  Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans , 2001, Psychopharmacology.

[29]  Rachael L Neve,et al.  CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Rothman,et al.  1-(m-Chlorophenyl)piperazine (mCPP) Dissociates In Vivo Serotonin Release from Long-Term Serotonin Depletion in Rat Brain , 2001, Neuropsychopharmacology.

[31]  T. Shippenberg,et al.  Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of μ- and κ-opioid agonists , 1987, Brain Research.

[32]  D. Cohen,et al.  Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study , 1993, Psychiatry Research.

[33]  Bryan L. Roth,et al.  Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Philip S. Portoghese,et al.  Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.

[35]  P. Renshaw,et al.  Antidepressant-like effects of cytidine in the forced swim test in rats , 2002, Biological Psychiatry.

[36]  Elyssa B. Margolis,et al.  κ-Opioid Agonists Directly Inhibit Midbrain Dopaminergic Neurons , 2003, The Journal of Neuroscience.

[37]  Paul Ernsberger,et al.  Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  B. H. Hill,et al.  An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence , 2000 .

[39]  M. Barrot,et al.  Regional and Cellular Mapping of cAMP Response Element-Mediated Transcription during Naltrexone-Precipitated Morphine Withdrawal , 2002, The Journal of Neuroscience.

[40]  R. Wise,et al.  Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. , 1993, The Journal of pharmacology and experimental therapeutics.

[41]  C. Konradi,et al.  Dopamine‐dependent increases in phosphorylation of cAMP response element binding protein (CREB) during precipitated morphine withdrawal in primary cultures of rat striatum , 2003, Journal of neurochemistry.

[42]  Elyssa B. Margolis,et al.  Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  P. von Voigtlander,et al.  Kappa agonist-induced reduction in dopamine release: site of action and tolerance. , 1992, Research communications in chemical pathology and pharmacology.

[44]  N. Hiroi,et al.  Regulation of cocaine reward by CREB. , 1998, Science.

[45]  Stanley J. Watson,et al.  The rat brain in stereotaxic coordinates (2nd edn) by George Paxinos and Charles Watson, Academic Press, 1986. £40.00/$80.00 (264 pages) ISBN 012 547 6213 , 1987, Trends in Neurosciences.

[46]  Bryan L Roth,et al.  Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. , 2005, Journal of medicinal chemistry.

[47]  C. Chavkin,et al.  κ Opioid Receptor Antagonism and Prodynorphin Gene Disruption Block Stress-Induced Behavioral Responses , 2003, The Journal of Neuroscience.